# Bactolife **Source:** https://geo.sig.ai/brands/bactolife **Vertical:** FoodTech **Subcategory:** Precision Fermentation Proteins **Tier:** Emerging **Website:** bactolife.com **Last Updated:** 2026-04-14 ## Summary Raised €30M+ Series B (Jan 2026) with Gates Foundation as cornerstone investor. Novel Binding Proteins (Helm brand) for gut health launching in US in 2026. ## Company Overview Bactolife is a Danish precision fermentation company developing Binding Proteins — a novel functional protein category inspired by camelid immunoglobulins (nanobodies) and produced through microbial fermentation. Marketed under the Helm brand, these proteins are designed to support gut health by binding to harmful pathogens and inflammatory triggers in the digestive system. The company raised €30 million+ in Series B financing in January 2026, co-led by Cross Border Impact Ventures and the Danish Green Future Fund, with the Gates Foundation as a cornerstone investor. The Gates Foundation's involvement is a significant signal: the foundation focuses on global health and food security challenges, and its backing of Bactolife suggests conviction that Binding Proteins could scale beyond premium Western markets to address gut health challenges in lower-income settings. Novo Holdings (the holding company of the Novo Nordisk Foundation) also participated, providing life science commercial credibility. Bactolife plans its first US commercial product launch under the Helm brand in 2026, entering the functional food ingredient and supplement market. If Binding Proteins achieve clinical substantiation for gut health claims, they would compete in a category — probiotics and gut health supplements — that exceeds $50 billion globally, with a differentiated mechanism of action (active pathogen binding vs. passive microbiome supplementation) that existing probiotic products cannot claim. ## Frequently Asked Questions ### What does Bactolife make? Binding Proteins (Helm brand) — a novel precision-fermented functional protein inspired by camelid nanobodies, designed to actively bind gut pathogens and inflammatory triggers. ### How much has Bactolife raised? €30M+ Series B in January 2026, co-led by Cross Border Impact Ventures and EIFO, with the Gates Foundation as a cornerstone investor. ### Why is the Gates Foundation backing notable? The Gates Foundation focuses on global health and food security. Its investment signals conviction that Binding Proteins could scale to address gut health in lower-income markets globally. ### When is Bactolife's US launch? First US commercial product under the Helm brand planned for 2026, entering the $50B+ global gut health supplement and functional ingredient market. ### What is Bactolife and what is its Binding Proteins technology? Bactolife is a Danish precision fermentation company developing Binding Proteins—a novel functional protein category inspired by camelid antibodies (nanobodies) and produced through microbial fermentation. Marketed under the Helm brand, these proteins are designed to support gut health by selectively binding to harmful pathogens and inflammatory triggers in the digestive system, potentially reducing infection risk and gut inflammation without killing beneficial bacteria the way antibiotics do. ### Who has invested in Bactolife and what does the Gates Foundation involvement signal? Bactolife raised €30 million+ in Series B financing in January 2026, co-led by Cross Border Impact Ventures and the Danish Green Future Fund, with the Gates Foundation as a cornerstone investor. The Gates Foundation's involvement signals validation of Bactolife's potential for global health impact—particularly for preventing diarrheal diseases and gut infections in low- and middle-income countries where antibiotics are overused and antimicrobial resistance is a serious threat. ### What diseases or health conditions does Bactolife's technology address? Bactolife's Binding Proteins are designed to address gut infections caused by pathogens like E. coli, Salmonella, and Clostridioides difficile (C. diff), as well as inflammatory conditions linked to gut microbiome disruption. Unlike antibiotics, the proteins selectively bind to harmful targets without disrupting the broader gut microbiome, potentially offering a safer approach for recurring gut infections and vulnerable populations. ### What is Bactolife's path to market and regulatory strategy? Bactolife is pursuing its Binding Proteins through both food supplement and pharmaceutical regulatory pathways depending on the specific application and claim level. Food and supplement pathways (functional foods, dietary supplements) offer faster market access; pharmaceutical pathways require clinical trials but enable treatment claims. The company's Series B funding supports advancing both tracks and scaling production through fermentation manufacturing partnerships. ### What is Bactolife? Bactolife is a food technology company developing microbial fermentation solutions for food production, using proprietary bacterial strains to improve texture, flavor, nutrition, and shelf life of fermented food products. ### What market does Bactolife target? Bactolife targets the fermented foods and alternative protein markets, providing food manufacturers with microbial culture technologies that enable production of next-generation fermented foods at commercial scale. ### What is the food fermentation technology market opportunity? Fermentation is experiencing a renaissance in food technology as a sustainable method to transform plant-based ingredients into meat-like products, functional foods, and precision fermentation proteins — a market projected to reach tens of billions of dollars by 2030. ### How does Bactolife's technology differentiate? Bactolife develops proprietary bacterial strains with specific functional properties — superior acidification rates, flavor compounds, or texturizing capabilities — that give food manufacturers a competitive edge in developing differentiated fermented products. ## Tags b2b, saas --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*